Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: Results from the 5-year long-term extension of the phase III pivotal trials

Nicolino Ruperto*, Hermine I. Brunner, Pierre Quartier, Tamàs Constantin, Nico M. Wulffraat, Gerd Horneff, Ozgur Kasapcopur, Rayfel Schneider, Jordi Anton, Judith Barash, Reinhard Berner, Fabrizia Corona, Ruben Cuttica, Marine Fouillet-Desjonqueres, Michel Fischbach, Helen E. Foster, Dirk Foell, Sebastião C. Radominski, Athimalaipet V. Ramanan, Ralf TrauzeddelErbil Unsal, Jérémy Levy, Eleni Vritzali, Alberto Martini, Daniel J. Lovell

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

41 Citations (Scopus)
224 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: Results from the 5-year long-term extension of the phase III pivotal trials'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds